StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies on Teva Pharma (TEVA): 'early, but investors should pay attention'
April 7, 2026 11:04 AM
Jefferies analyst Dennis Ding reiterated a Buy rating and $40.00 price target on Teva Pharma (NYSE: TEVA)The analyst commented, "TEVA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
